


Figure S1

A



B




Figure S1. In silico analysis to determine potential c-Abl mitochondrial targets.

(A) Workflow of the in silico analysis in which 1136 proteins from the MitoCarta 3.0 data set were filtered under the “mitochondrial dynamic and surveillance” pathway, resulting in 40 proteins, from which FASTA sequence was obtained in UniProt data base and run for c-Abl kinase dependent analysis in the GPS 5.0 software with a medium cut-off. The residues that had a bigger value that cut off value were searched in the PhosphoNET online tool for Hydrophobicity- dependent analysis. The score was calculated as the multiplication between the kinase-dependent predicted value, the hydrophobicity-dependent value and -1 to correct the negative values of the hydrophobicity analysis.

(B) Y269 in MFN2 is conserved in a wide range of species from which a phylogenetic tree is shown.

Figure S2





Figure S2. Stable overexpression of FLAG-Mfn2 restitutes the mitochondrial morphology in Mfn1/2- deficient MEF cells.

(A) Protein levels of MFN2 and FLAG in stable expression of MFN2 variants in Mfn1/2- deficient MEF cells.

(B) Microscopy for cerulean-OMM marker (cyan) showing mitochondrial morphology in stable expression of MFN2 variants in Mfn1/2- deficient MEF cells.

Figure S3





Figure S3. GTP hydrolytic rate is not altered in mutant Mfn2.


GTP assay detecting released Pi at 620 nm from immunoprecipitated Mfn2-FLAG

Figure S4


A



B



C



A: Oligomycin (0.5uM)

B: FCCP (0.5uM)

C: Rotenone (0.5uM) + Antimycin A (1uM)

Figure S5. Mitochondrial activity in MFN WT and Y269F mutant MEF


(A) OCR in MFN WT and Y269F mutant MEF expressed as pMoles/mln.

(B) OCR in MFN WT and Y269F mutant MEF expressed as percentage (%) respect to basal condition.

(C) ECAR in MFN WT and Y269F mutant MEF expressed as mpH/mln.

Figure S5

A



B




Figure S5. Pharmacological inhibition of c-Abl improves ALS phenotype in SOD1 G93A mice.

(A) Kaplan-Meier curve shows the probability of onset of symptoms in control-fed (black line, n=11), nilotinib-fed (blue line, n=14) and neurotinib-fed (yellow line, n=13) SOD1 G93A mice using log-rank (Mantel-Cox) test.

(B) Kaplan-Meier survival curve shows the probability of death in the same groups of mice using log-rank (Mantel-Cox) test.